Temat: "Carcinoma, Transitional Cell" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.
Autorzy:: Wu J; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Lin Y; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin, 300211, People's Republic of China.; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yang K; Department of Urology, Peking University First Hospital, No. 8 Xishiku Dajie, Xicheng District, Beijing, 100034, People's Republic of China.
Liu X; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Wang H; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Yu T; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Tao R; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Guo J; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Chen L; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Cheng H; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
Lou F; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China. .
Cao S; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China. .
Yu W; Department of Urology, Peking University First Hospital, No. 8 Xishiku Dajie, Xicheng District, Beijing, 100034, People's Republic of China. .
Hu H; Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Hexi District, Tianjin, 300211, People's Republic of China. .; Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China. .
Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. .; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. .; Pokaż więcej
Źródło:: Molecular cancer [Mol Cancer] 2024 Mar 19; Vol. 23 (1), pp. 57. Date of Electronic Publication: 2024 Mar 19.
Typ publikacji:: Randomized Controlled Trial; Multicenter Study; Letter; Research Support, Non-U.S. Gov't
MeSH Terms:: Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/urine
Humans ; Retrospective Studies ; Prospective Studies ; Sensitivity and Specificity ; Treatment Outcome ; DNA ; Biomarkers, Tumor/genetics ; Transcription Factors ; Homeodomain Proteins

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Surgery for pulmonary lesions in patients with a history of urinary tract transitional cell carcinoma.
Autorzy:: Kanzaki R; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan. .
Nagoya A; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Taniguchi S; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Ishida H; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Kimura K; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Fukui E; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Kimura T; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Kanou T; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Ose N; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Funaki S; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Minami M; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.
Morii E; Department of Pathology, Osaka University Graduate School of Medicine, Suita, Japan.
Shintani Y; Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, L5-2-2 Yamadaoka, Suita-City, Osaka, 565-0871, Japan.; Pokaż więcej
Źródło:: Journal of cardiothoracic surgery [J Cardiothorac Surg] 2024 Mar 12; Vol. 19 (1), pp. 117. Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/pathology
Carcinoma, Transitional Cell*/surgery
Lung Neoplasms*/surgery
Urinary Tract*/pathology
Humans ; Male ; Female ; Aged ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
Autorzy:: Zhang J; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yang M; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Wei D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zhang D; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chen Z; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .
Zhu H; Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 13; Vol. 24 (1), pp. 202. Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/surgery
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Antibodies, Monoclonal, Humanized*
Humans ; Cisplatin/therapeutic use ; Gemcitabine ; Retrospective Studies ; Deoxycytidine/adverse effects ; Muscles ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Autorzy:: Minato A; Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Furubayashi N; Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
Nagata Y; Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Tomoda T; Department of Urology, Oita Prefectural Hospital, Oita 870-8511, Japan.
Masaoka H; Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan.
Song Y; Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan.
Hori Y; Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 880-8510, Japan.
Kiyoshima K; Department of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka 815-8555, Japan.
Negishi T; Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
Kuroiwa K; Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 880-8510, Japan.
Seki N; Department of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka 815-8588, Japan.
Tomisaki I; Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Harada K; Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.
Nakamura M; Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan.
Fujimoto N; Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Feb 03; Vol. 31 (2), pp. 862-871. Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study
MeSH Terms:: Antibodies, Monoclonal*
Carcinoma, Transitional Cell*/drug therapy
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*
Humans ; Prognosis ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Xanthogranulomatous Ureteritis: A Diagnostic Challenge in a Patient with Bladder Cancer.
Autorzy:: Nova-Camacho LM; Department of Pathology, Donostia University Hospital, San Sebastian, Spain.
Val-Carreres Castellote A; Department of Pathology, Donostia University Hospital, San Sebastian, Spain.
Villafruela Mateos A; Department of Urology, Donostia University Hospital, San Sebastian, Spain.; Pokaż więcej
Źródło:: International journal of surgical pathology [Int J Surg Pathol] 2024 Feb; Vol. 32 (1), pp. 182-186. Date of Electronic Publication: 2023 May 04.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Urinary Bladder Neoplasms*/complications
Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/surgery
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/surgery
Carcinoma, Transitional Cell*/pathology
Ureter*/surgery
Ureter*/pathology
Urinary Tract Infections*/pathology
Gastrointestinal Diseases*/pathology
Male ; Humans ; Middle Aged ; Inflammation/pathology ; Granuloma/pathology ; Plasma Cells/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Noninvasive Papillary Urothelial Carcinoma of the Bladder: An Institutional Experience Focusing on Tumors With Borderline Features.
Autorzy:: Oliver-Krasinski JM; From the Department of Pathology, Montefiore Medical Center, Bronx, New York (Oliver-Krasinski).
Bidot S; the Department of Pathology, Emory University School of Medicine, Atlanta, Georgia (Bidot, Tinsley, Harik).
Ingram JW; the Department of Urology, Columbia University Irving Medical Center, New York, New York (Ingram, McKiernan).
O'Toole KM; the Department of Pathology and Cell Biology, Columbia University, New York, New York (O'Toole).
McKiernan JM; the Department of Urology, Columbia University Irving Medical Center, New York, New York (Ingram, McKiernan).
Tinsley M; the Department of Pathology, Emory University School of Medicine, Atlanta, Georgia (Bidot, Tinsley, Harik).
Harik LR; the Department of Pathology, Emory University School of Medicine, Atlanta, Georgia (Bidot, Tinsley, Harik).; Pokaż więcej
Źródło:: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2024 Feb 01; Vol. 148 (2), pp. 223-229.
Typ publikacji:: Review; Journal Article
MeSH Terms:: Urinary Bladder Neoplasms*/therapy
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/therapy
Carcinoma, Transitional Cell*/pathology
Carcinoma in Situ*
Humans ; Urinary Bladder/pathology ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
Autorzy:: Zhang C; Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang , China.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Xu X; Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang , China.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Wang T; Jiangsu MicroDiag Biomedicine Co., Ltd., Suzhou, China.
Lu Y; Jiangsu MicroDiag Biomedicine Co., Ltd., Suzhou, China.
Lu Z; Jiangsu MicroDiag Biomedicine Co., Ltd., Suzhou, China.
Wang T; Jiangsu MicroDiag Biomedicine Co., Ltd., Suzhou, China.
Pan Z; Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang , China. pan_.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China. pan_.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Apr 04; Vol. 14 (1), pp. 7941. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:: Journal Article
MeSH Terms:: Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/pathology
Humans ; Urinary Bladder/pathology ; Vimentin/genetics ; Biomarkers, Tumor/metabolism ; DNA Methylation/genetics ; Nuclear Proteins/genetics ; Twist-Related Protein 1/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
Autorzy:: Wei T; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yuan P; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.; Pokaż więcej
Źródło:: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Mar 23; Vol. 46 (3), pp. 211-220.
Typ publikacji:: English Abstract; Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*
Urinary Bladder Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Immunoconjugates*/therapeutic use
Receptor, ErbB-2*
Humans ; Oncogenes

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Autorzy:: Kdimati S; Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany.
Christoph C; Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany.
Glass Ä; Institute of Biostatistics and Informatics in Medicine and Aging Research, Rostock University Medical Center, 18057 Rostock, Germany.
Engel N; Department of Oral, Maxillofacial and Plastic Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Dräger DL; Department of Urology, Rostock University Medical Center, 18057 Rostock, Germany.
Maletzki C; Department of Internal Medicine, Medical Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, 18057 Rostock, Germany.
Becker AS; Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany.
Zimpfer A; Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 20; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 20.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/metabolism
Urinary Bladder Neoplasms*
Humans ; B7-H1 Antigen ; Prognosis ; Retrospective Studies ; Ligands ; Apoptosis ; Biomarkers ; Chemokines ; MARVEL Domain-Containing Proteins/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Autorzy:: Hu P; EMD Serono, Billerica, Massachusetts, USA.
Dai HI; EMD Serono, Billerica, Massachusetts, USA.
Bourdage J; the healthcare business of Merck KGaA, Darmstadt, Germany.
Zhou D; the healthcare business of Merck KGaA, Darmstadt, Germany.
Trang K; the healthcare business of Merck KGaA, Darmstadt, Germany.
Kowalski K; Pfizer, La Jolla, California, USA.
Bello C; Pfizer, San Diego, California, United States.
Hibma J; Pfizer, San Diego, California, United States.
Khandelwal A; the healthcare business of Merck KGaA, Darmstadt, Germany.
Cowan K; the healthcare business of Merck KGaA, Darmstadt, Germany.
Dong J; EMD Serono, Billerica, Massachusetts, USA.
Venkatakrishnan K; EMD Serono, Billerica, Massachusetts, USA.
Gao W; EMD Serono, Billerica, Massachusetts, USA.; Pokaż więcej
Źródło:: Clinical and translational science [Clin Transl Sci] 2024 Mar; Vol. 17 (3), pp. e13730.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Merkel Cell*/drug therapy
Carcinoma, Merkel Cell*/pathology
Carcinoma, Transitional Cell*/drug therapy
Skin Neoplasms*/drug therapy
Skin Neoplasms*/pathology
Urinary Bladder Neoplasms*
Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Clinical Trials as Topic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
Autorzy:: Huang LH; Department of Urology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.; Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung, Taiwan.
Chen CS; Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Li JR; Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Chiu KY; Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Wang SS; Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Yang CK; Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Cheng CL; Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Lin CC; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan. .; Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan. .; The iEGG and Animal Biotechnology Center, Advanced Plant and Food Crop Biotechnology Center, National Chung-Hsing University, Taichung, Taiwan. .; Department of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. .; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. .
Ou YC; Department of Urology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan. .; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan. .; Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung, Taiwan. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Feb 22; Vol. 24 (1), pp. 247. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/surgery
Ureteral Neoplasms*/pathology
Urologic Neoplasms*/surgery
Urologic Neoplasms*/pathology
Carcinoma, Squamous Cell*/surgery
Humans ; Nephroureterectomy ; Retrospective Studies ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/surgery ; Prognosis ; Epithelial Cells/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
Autorzy:: Saad R; Department of Pharmacy, American University of Beirut Medical Center, Riad El-Solh, P.O. Box 11-0236, Beirut, 1107 2020, Lebanon.
Ghaddar A; Department of Pharmacy, American University of Beirut Medical Center, Riad El-Solh, P.O. Box 11-0236, Beirut, 1107 2020, Lebanon.
Zeenny RM; Department of Pharmacy, American University of Beirut Medical Center, Riad El-Solh, P.O. Box 11-0236, Beirut, 1107 2020, Lebanon. rony_.; INSPECT-LB (Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban), Beirut, Lebanon. rony_.; Pokaż więcej
Źródło:: Journal of medical case reports [J Med Case Rep] 2024 Feb 22; Vol. 18 (1), pp. 107. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:: Review; Case Reports; Journal Article
MeSH Terms:: Myocarditis*/chemically induced
Urinary Bladder Neoplasms*/drug therapy
Carcinoma, Transitional Cell*
Atrioventricular Block*/chemically induced
Atrioventricular Block*/complications
Atrioventricular Block*/drug therapy
Antineoplastic Agents, Immunological*/adverse effects
Myositis*/chemically induced
Myositis*/drug therapy
Antibodies, Monoclonal, Humanized*
Humans ; Female ; Aged, 80 and over ; Creatine Kinase

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.
Autorzy:: Boddu VK; Department of Hematology and Oncology, Section for Experimental Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Zamzow P; Department of Hematology and Oncology, Section for Experimental Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Kramer MW; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Merseburger AS; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Gorantla SP; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Klinger M; Institute of Anatomy, University of Lübeck, Lübeck, Germany.
Cramer L; Department of Hematology and Oncology, Section for Experimental Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Sauer T; Department of Surgery, Section for Translational Surgical Oncology and Biobanking, University Hospital Schleswig-Holstein, Lübeck, Germany.
Gemoll T; Department of Surgery, Section for Translational Surgical Oncology and Biobanking, University Hospital Schleswig-Holstein, Lübeck, Germany.
von Bubnoff N; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), Lübeck, Germany.
Gieseler F; Department of Hematology and Oncology, Section for Experimental Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), Lübeck, Germany.
Darabi M; Department of Hematology and Oncology, Section for Experimental Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany. .; University Cancer Center Schleswig-Holstein (UCCSH), Lübeck, Germany. .; Pokaż więcej
Źródło:: Cell communication and signaling : CCS [Cell Commun Signal] 2024 Feb 15; Vol. 22 (1), pp. 129. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Transitional Cell*/drug therapy
Extracellular Vesicles*/drug effects
Lipoproteins*/metabolism
Urinary Bladder Neoplasms*/drug therapy
Basigin*/antagonists & inhibitors
Humans ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
Autorzy:: Ali M; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. .; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. .
Koo K; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Chang D; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Chan P; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Oon SF; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
Moon D; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Murphy DG; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Eapen R; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Goad J; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Surgery, St. Vincent's Hospital, Melbourne, Australia.
Lawrentschuk N; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Urology, Royal Melbourne Hospital, Melbourne, Australia.
Azad AA; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Chander S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Clinical Pathology, University of Melbourne, Melbourne, Australia.
Shaw M; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Hardcastle N; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Australia.; Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW, Australia.
Siva S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2024 Feb 15; Vol. 19 (1), pp. 23. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Renal Cell*/surgery
Carcinoma, Renal Cell*/radiotherapy
Kidney Neoplasms*/surgery
Kidney Neoplasms*/pathology
Carcinoma, Transitional Cell*
Urinary Bladder Neoplasms*
Radiosurgery*/adverse effects
Radiosurgery*/methods
Kidney Failure, Chronic*/etiology
Renal Insufficiency, Chronic*/etiology
Adult ; Humans ; Aged ; Aged, 80 and over ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma.
Autorzy:: Lee CU; Department of Urology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Gyeonggi-do, Republic of Korea.
Lee JH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Lee HW; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Chung JH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Song W; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Kang M; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Jeon HG; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Jeong BC; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Seo SI; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Jeon SS; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.
Sung HH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Feb 12; Vol. 14 (1), pp. 3497. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:: Journal Article
MeSH Terms:: Ureter*/surgery
Ureter*/pathology
Ureteral Neoplasms*
Carcinoma, Transitional Cell*/pathology
Urinary Bladder Neoplasms*/surgery
Kidney Neoplasms*/pathology
Humans ; Nephroureterectomy ; Nephrectomy ; Disease Progression ; Retrospective Studies ; Neoplasm Recurrence, Local/surgery

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Diffuse Carbonic Anhydrase 9 and GATA3 Expression in Fumarate Hydratase Deficient Renal Cell Carcinoma - A Case Report and Immunoprofile Review.
Autorzy:: Pacheco RR; Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
Pacheco R; Department of Radiology, Albany Medical Center, Albany, NY, USA.
Cooley C; Department of Radiology, Albany Medical Center, Albany, NY, USA.
Kaufman R; Department of Urology, Albany Medical Center, Albany, NY, USA.
Akgul M; Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.; Pokaż więcej
Źródło:: International journal of surgical pathology [Int J Surg Pathol] 2024 Feb; Vol. 32 (1), pp. 145-149. Date of Electronic Publication: 2023 Apr 12.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Carcinoma, Renal Cell*/diagnosis
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/diagnosis
Kidney Neoplasms*/pathology
Carcinoma, Transitional Cell*
Urinary Bladder Neoplasms*
Humans ; Fumarate Hydratase/genetics ; Carbonic Anhydrase IX ; GATA3 Transcription Factor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Plasmacytoid urothelial carcinoma with duodenal metastasis-A rare tumor with unusual site of metastasis with grim outcome.
Autorzy:: Chenniappan A; Department of Pathology (Histopathology Section), Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Stephen NS; Department of Pathology (Histopathology Section), Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Srinivas BH; Department of Pathology (Histopathology Section), Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Sreenivasan SK; Department of Urology and Renal Transplantation, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Govindarajalou R; Department of Radiodiagnosis, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.; Pokaż więcej
Źródło:: Indian journal of pathology & microbiology [Indian J Pathol Microbiol] 2024 Jan-Mar; Vol. 67 (1), pp. 175-177.
Typ publikacji:: Case Reports
MeSH Terms:: Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/pathology
Plasmacytoma*
Humans ; Retrospective Studies ; Urinary Bladder/pathology ; Cystectomy/methods

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Qualification of the Microsatellite Instability Analysis (MSA) for Bladder Cancer Detection: The Technical Challenges of Concordance Analysis.
Autorzy:: Reynolds T; NEXT Bio-Research Services, LLC, 11601 Ironbridge Road, Suite 101, Chester, VI 23831, USA.
Bertsche K; NEXT Bio-Research Services, LLC, 11601 Ironbridge Road, Suite 101, Chester, VI 23831, USA.
Moon D; HJM Cancer Research Foundation Corporation, 10606 Candlewick Road, Lutherville, MD 21093, USA.
Moon C; HJM Cancer Research Foundation Corporation, 10606 Candlewick Road, Lutherville, MD 21093, USA.; BCD Innovations USA, 10606 Candlewick Road, Lutherville, MD 21093, USA.; Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins Medical Institution, Cancer Research Building II, 5M3, 1550 Orleans Street, Baltimore, MD 21205, USA.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 22; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 22.
Typ publikacji:: Journal Article
MeSH Terms:: Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/genetics
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/genetics
Humans ; Urinary Bladder ; Microsatellite Instability ; Biomarkers

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial Carcinoma: A Case Report and Review of the Literature.
Autorzy:: Pescia C; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Pini G; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Lopez G; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Malfatto M; Division of Urology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Brescia G; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
Tabano S; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.; Molecular Genetics Laboratory, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Del Gobbo A; Division of Pathology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Pokaż więcej
Źródło:: International journal of surgical pathology [Int J Surg Pathol] 2023 Dec; Vol. 31 (8), pp. 1572-1579. Date of Electronic Publication: 2023 Mar 20.
Typ publikacji:: Review; Case Reports; Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/pathology
Hamartoma*/diagnosis
Hamartoma*/surgery
Hamartoma*/pathology
Urinary Bladder Neoplasms*/diagnosis
Urinary Bladder Neoplasms*/surgery
Urinary Bladder Neoplasms*/pathology
Humans ; Urinary Bladder/surgery ; Urinary Bladder/pathology ; Urologic Surgical Procedures

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: An Unusual Presentation of Metastatic BK Virus-Associated Urothelial Carcinoma Arising in the Allograft, Persisting After Transplant Nephrectomy.
Autorzy:: Jones H; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Bhakta A; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas TX, USA.
Jia L; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Wojciechowski D; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas TX, USA.
Torrealba J; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.; Pokaż więcej
Źródło:: International journal of surgical pathology [Int J Surg Pathol] 2023 Dec; Vol. 31 (8), pp. 1586-1592. Date of Electronic Publication: 2023 Apr 03.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Kidney Transplantation*/adverse effects
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/surgery
BK Virus*/physiology
Urinary Bladder Neoplasms*/complications
Tumor Virus Infections*/complications
Tumor Virus Infections*/diagnosis
Male ; Humans ; Adult ; Viremia/complications ; Viremia/drug therapy ; Allografts ; Nephrectomy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 21.

Tytuł:: Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature.
Autorzy:: Liu L; Department of Urology, Baoding No. 1 Central Hospital, Baoding, P.R. China.; Prostate and Andrology Key Laboratory of Baoding, Baoding No. 1 Central Hospital, Baoding, P.R. China.
Sun FZ; Department of Surgery and Urology, Hebei General Hospital, Shijiazhuang, P.R. China.
Zhang PY; Department of Surgery and Urology, Hebei General Hospital, Shijiazhuang, P.R. China.
Xiao Y; Psychosomatic Medical Center, The Fourth People's Hospital of Chengdu, Chengdu, P.R. China.; Psychosomatic Medical Center, The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, P.R. China.
Yue X; Department of Urology, Baoding No. 1 Central Hospital, Baoding, P.R. China.; Prostate and Andrology Key Laboratory of Baoding, Baoding No. 1 Central Hospital, Baoding, P.R. China.
Wang DM; Department of Urology, Baoding No. 1 Central Hospital, Baoding, P.R. China.; Prostate and Andrology Key Laboratory of Baoding, Baoding No. 1 Central Hospital, Baoding, P.R. China.
Wang Q; Department of Urology, Baoding No. 1 Central Hospital, Baoding, P.R. China.; Prostate and Andrology Key Laboratory of Baoding, Baoding No. 1 Central Hospital, Baoding, P.R. China.; Pokaż więcej
Źródło:: The aging male : the official journal of the International Society for the Study of the Aging Male [Aging Male] 2023 Dec; Vol. 26 (1), pp. 2252102.
Typ publikacji:: Review; Case Reports; Journal Article
MeSH Terms:: Prostatic Hyperplasia*/complications
Prostatic Hyperplasia*/diagnostic imaging
Carcinoma, Transitional Cell*/complications
Carcinoma, Transitional Cell*/diagnostic imaging
Prostatic Neoplasms*/complications
Prostatic Neoplasms*/diagnostic imaging
Urinary Bladder Neoplasms*
Male ; Humans ; Aged ; Prostate/diagnostic imaging ; Magnetic Resonance Imaging

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 22.

Tytuł:: Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review.
Autorzy:: Li D; Department of Pathology, the Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an, 271000, China.
Liu F; Department of Urology, the Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an, 271000, China.
Chen Y; Department of Rehabilitation, the Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an, 271000, China.
Li P; Department of Pathology, the Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an, 271000, China.
Liu Y; Department of Hematology, the Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an, 271000, China.
Pang Y; Department of Pathology, the Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an, 271000, China. .; Pokaż więcej
Źródło:: Diagnostic pathology [Diagn Pathol] 2023 Nov 03; Vol. 18 (1), pp. 120. Date of Electronic Publication: 2023 Nov 03.
Typ publikacji:: Case Reports; Review; Journal Article
MeSH Terms:: Carcinoma, Renal Cell*/pathology
Carcinoma, Transitional Cell*/diagnosis
Carcinoma, Transitional Cell*/genetics
Carcinoma, Transitional Cell*/pathology
Kidney Neoplasms*/genetics
Kidney Neoplasms*/pathology
Kidney Transplantation*/adverse effects
Neoplasms, Multiple Primary*/genetics
Neoplasms, Multiple Primary*/pathology
Urinary Bladder Neoplasms*/genetics
Aged ; Female ; Humans ; Histone Demethylases ; Kidney/pathology ; Proto-Oncogene Proteins p21(ras)

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 23.

Tytuł:: Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Autorzy:: Iida K; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.; Department of Urology, Gamagori City Hospital, Gamagori City, Japan.
Naiki T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. .
Etani T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Nagai T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Sugiyama Y; Department of Pharmacy, Nagoya City University Hospital, Nagoya, Japan.
Isobe T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Aoki M; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Nozaki S; Department of Urology, Anjo Kosei Hospital, Anjo City, Japan.
Noda Y; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.; Department of Urology, Toyota Kosei Hospital, Toyota City, Japan.
Shimizu N; Department of Urology, Anjo Kosei Hospital, Anjo City, Japan.
Tomiyama N; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.; Department of Urology, Gamagori City Hospital, Gamagori City, Japan.
Gonda M; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Kamiya H; Department of Urology, Daido Hospital, Nagoya City, Japan.
Kubota H; Department of Urology, Kainan Hospital, Yatomi City, Japan.
Nakane A; Department of Urology, Gamagori City Hospital, Gamagori City, Japan.; Department of Education and Research Center for Community Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Ando R; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Kawai N; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Yasui T; Department of Nephro-urology, Graduate School of Medical Sciences, Nagoya City University, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2024 Jan 30; Vol. 14 (1), pp. 2520. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/drug therapy
Urinary Bladder Neoplasms*/pathology
Metformin*/therapeutic use
Antibodies, Monoclonal, Humanized*
Humans ; Proton Pump Inhibitors/pharmacology ; Proton Pump Inhibitors/therapeutic use ; Retrospective Studies ; Anti-Bacterial Agents/therapeutic use ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Steroids/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 24.

Tytuł:: Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
Autorzy:: Endo Y; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Akatsuka J; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Takeda H; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Hasegawa H; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Yanagi M; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Toyama Y; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Mikami H; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Shibasaki M; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Kimura G; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Kondo Y; Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2024 Jan 29; Vol. 31 (2), pp. 759-768. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Transitional Cell*/drug therapy
Urinary Bladder Neoplasms*
Antibodies, Monoclonal*
Humans ; Male ; Female ; Japan ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 25.

Tytuł:: Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
Autorzy:: Kvikstad V; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.
Lillesand M; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.
Gudlaugsson E; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
Mangrud OM; Cancer Registry of Norway, Oslo, Norway.
Rewcastle E; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.
Skaland I; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.
Baak JPA; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Dr. Med. Jan Baak AS, Tananger, Norway.
Janssen EAM; Department of Pathology, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Jan 26; Vol. 19 (1), pp. e0297141. Date of Electronic Publication: 2024 Jan 26 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Urinary Bladder Neoplasms*/pathology
Carcinoma, Transitional Cell*/pathology
Carcinoma in Situ*/pathology
Humans ; Tumor Suppressor Protein p53 ; Immunohistochemistry ; Neoplasm Recurrence, Local ; Retrospective Studies ; Biomarkers, Tumor ; Ki-67 Antigen/metabolism ; Prognosis ; Cell Proliferation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Carcinoma, Transitional Cell"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język